Literature DB >> 28334603

The CB1 Receptor as the Cornerstone of Exostasis.

Pier Vincenzo Piazza1, Daniela Cota2, Giovanni Marsicano3.   

Abstract

The type-1 cannabinoid receptor (CB1) is the main effector of the endocannabinoid system (ECS), which is involved in most brain and body functions. In this Perspective, we provide evidence indicating that CB1 receptor functions are key determinants of bodily coordinated exostatic processes. First, we will introduce the concepts of endostasis and exostasis as compensation or accumulation for immediate or future energy needs and discuss how exostasis has been necessary for the survival of species during evolution. Then, we will argue how different specific biological functions of the CB1 receptor in the body converge to provide physiological exostatic processes. Finally, we will introduce the concept of proactive evolution-induced diseases (PEIDs), which helps explain the seeming paradox that an evolutionary-selected physiological function can become the cause of epidemic pathological conditions, such as obesity. We propose here a possible unifying theory of CB1 receptor functions that can be tested by future experimental studies.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28334603     DOI: 10.1016/j.neuron.2017.02.002

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  26 in total

1.  [Cannabinoids in pain medicine].

Authors:  M Karst
Journal:  Schmerz       Date:  2018-10       Impact factor: 1.107

Review 2.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

3.  Transient gain of function of cannabinoid CB1 receptors in the control of frontocortical glucose consumption in a rat model of Type-1 diabetes.

Authors:  Joana Reis Pedro; Liane I F Moura; Ângela Valério-Fernandes; Filipa I Baptista; Joana M Gaspar; Bárbara S Pinheiro; Cristina Lemos; Fernanda Neutzling Kaufmann; Carla Morgado; Carla S da Silva-Santos; Isaura Tavares; Samira G Ferreira; Eugénia Carvalho; António F Ambrósio; Rodrigo A Cunha; João M N Duarte; Attila Köfalvi
Journal:  Brain Res Bull       Date:  2020-05-16       Impact factor: 4.077

4.  Endocannabinoid regulation of homeostatic feeding and stress-induced alterations in food intake in male rats.

Authors:  Martin A Sticht; David J Lau; Catherine M Keenan; Jean-Baptiste Cavin; Maria Morena; Venkata Kiran Vemuri; Alexandros Makriyannis; Benjamin F Cravatt; Keith A Sharkey; Matthew N Hill
Journal:  Br J Pharmacol       Date:  2018-08-22       Impact factor: 8.739

5.  Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice.

Authors:  Carmelo Quarta; Daniela Cota
Journal:  Int J Obes (Lond)       Date:  2020-04-21       Impact factor: 5.095

6.  Chronic insulinopenia/hyperglycemia decreases cannabinoid CB1 receptor density and impairs glucose uptake in the mouse forebrain.

Authors:  Liane I F Moura; Cristina Lemos; Catherine Ledent; Eugénia Carvalho; Attila Köfalvi
Journal:  Brain Res Bull       Date:  2019-02-02       Impact factor: 4.077

Review 7.  Progress on the application of positron emission tomography imaging of cannabinoid type 1 receptor in neuropsychiatric diseases.

Authors:  Lijuan Ma; Shuang Wu; Kai Zhang; Mei Tian; Hong Zhang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-10-25

Review 8.  Metabolic Messengers: endocannabinoids.

Authors:  Arnau Busquets-García; Juan P Bolaños; Giovanni Marsicano
Journal:  Nat Metab       Date:  2022-07-11

9.  Neurobiological Considerations for Tobacco Use Disorder.

Authors:  Megha Chawla; Kathleen A Garrison
Journal:  Curr Behav Neurosci Rep       Date:  2018-10-30

10.  Combined Loss of Ghrelin Receptor and Cannabinoid CB1 Receptor in Mice Decreases Survival but does not Additively Reduce Body Weight or Eating.

Authors:  Bharath K Mani; Carlos M Castorena; Claudia R Vianna; Charlotte E Lee; Nathan P Metzger; Prasanna Vijayaraghavan; Sherri Osborne-Lawrence; Joel K Elmquist; Jeffrey M Zigman
Journal:  Neuroscience       Date:  2019-09-12       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.